Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Review Article

Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future

Author(s): Zexi Liao, Jiaxin Li, Jingjing Wu, Jing Liu* and Shuming Sun*

Volume 21 , Issue 10 , 2021

Published on: 21 January, 2021

Page: [819 - 831] Pages: 13

DOI: 10.2174/1566524021666210121142316

Price: $65

Abstract

Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML) with features such as accumulation of maturation-arrested erythroblasts. Compared with AML, the progression of AEL is faster and the prognosis to available therapy is worse. However, its categorization is still being updated and the pathophysiology of AEL is still under research, making diagnosis and chemotherapy challenging for physicians. To achieve better outcomes, therapies should be optimized and new drugs should be developed. In this review, we summarize current strategies of diagnosis and therapies of AEL, and discuss prospective targets for chemotherapeutic agents based on the biological characteristics of AEL neoplastic cells as well as transcriptional factors and pathways related to erythroid differentiation.

Keywords: Acute erythroid leukemia, acute myeloid leukemia, chemotherapeutic agents, erythroid differentiation, GATA-1, GATA-2, Gfi1b, EKLF, EPO-related pathways.

Next »

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy